Evoke Pharma, Inc. Reports Third Quarter 2024 Financial Results
November 07, 2024 16:05 ET
|
Evoke Pharma, Inc.
GIMOTI third quarter net product sales of $2.7 million, highest quarterly revenue ever with a 70% increase year-over-year Strong cumulative prescriber growth, 45% year-over-year increase 52%...
Evoke Pharma & EVERSANA Announce Statistically Significant Improvement in Patient Outcomes for GLP-1 users with Diabetic Gastroparesis using GIMOTI®
October 28, 2024 07:00 ET
|
Evoke Pharma, Inc.
Analysis of real-world data compared patients on GIMOTI (n=51) to Oral Metoclopramide (n=41), both taking GLP-1s, showing significant statistical improvement for GIMOTI over Oral Metoclopramide in All...
Evoke Pharma to Showcase Award-Winning Research at the 2024 American College of Gastroenterology Annual Scientific Meeting
October 23, 2024 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
Evoke Pharma Announces the Appointment of Ben Smeal to the Board of Directors
October 22, 2024 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
Evoke Pharma Announces Proceeds from Existing Warrants and Board Expansion
October 01, 2024 08:30 ET
|
Evoke Pharma, Inc.
Nantahala to nominate 2 board seats Portion of the proceeds received from warrants executed at $8.16/share SOLANA BEACH, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc....
Evoke Pharma Reaffirms Its Commitment to Patients with Gastroparesis Amid Industry Developments
September 19, 2024 14:20 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
Evoke Pharma, Inc. Reports Second Quarter 2024 Financial Results
August 13, 2024 08:00 ET
|
Evoke Pharma, Inc.
GIMOTI second quarter net product sales grew 47% quarter-over-quarter and 126% year-over-year, indicating an annual run-rate in excess of $10 million Achieved record-high prescription fills...
Evoke Pharma, Inc. Supports Gastroparesis Awareness Month
August 08, 2024 08:30 ET
|
Evoke Pharma, Inc.
Collaborating with advocacy groups to amplify gastroparesis awareness for millions of patients worldwide Call for action to improve health and access for patients SOLANA BEACH, Calif., Aug....
Evoke Pharma, Inc. Announces Reverse Stock Split
July 30, 2024 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
Evoke Pharma Reports Commercial Strategy Progress & Positive Momentum for GIMOTI
June 17, 2024 08:30 ET
|
Evoke Pharma, Inc.
Expanded State Medicaid Access for GIMOTI Achieved highest ever monthly GIMOTI prescription fills in May 2024 Promoted former VP of Finance, Mark Kowieski to Chief Financial Officer SOLANA...